{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:09Z","timestamp":1786119309274,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1097\/ftd.0b013e3181aa4780","type":"journal-article","created":{"date-parts":[[2009,7,21]],"date-time":"2009-07-21T03:31:17Z","timestamp":1248147077000},"page":"475-481","source":"Crossref","is-referenced-by-count":35,"title":["Serum Levels of Risperidone and Its Metabolite, 9-Hydroxyrisperidone: Correlation Between Drug Concentration and Clinical Response"],"prefix":"10.1097","volume":"31","author":[{"given":"Alfonso M","family":"Lostia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Mazzarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Pacchiarotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Lionetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro De","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Sanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Sani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio D","family":"Kotzalidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Simmaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Tatarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"3","key":"R1-8-20210129","first-page":"CD002306","article-title":"Risperidone versus other atypical antipsychotic medication for schizophrenia.","author":"Gilbody","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"R2-8-20210129","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1176\/ajp.156.6.869","article-title":"Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.","volume":"156","author":"Nyberg","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R3-8-20210129","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1185\/030079904X2312","article-title":"A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone.","volume":"20","author":"Mintzer","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"R4-8-20210129","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1517\/14656566.1.7.1441","article-title":"Pharmacology and clinical experience with risperidone.","volume":"1","author":"Love","year":"2000","journal-title":"Expert Opin Pharmacother"},{"key":"R5-8-20210129","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","article-title":"Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology.","volume":"162","author":"McDougle","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R6-8-20210129","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/0269881106062894","article-title":"The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.","volume":"20","author":"Plesnicar","year":"2006","journal-title":"J Psychopharmacol"},{"key":"R7-8-20210129","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1176\/appi.ajp.162.5.1010","article-title":"Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.","volume":"162","author":"Knegtering","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R8-8-20210129","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0269881107077357","article-title":"Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.","volume":"21","author":"Wang","year":"2007","journal-title":"J Psychopharmacol"},{"key":"R9-8-20210129","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1570-0232(02)00715-8","article-title":"Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry.","volume":"783","author":"Remmerie","year":"2003","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R10-8-20210129","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2125.2003.02061.x","article-title":"Effects of various factors on steady-state plasma concentrations of risperidone and 9 hydroxyrisperidone: lack of impact of MDR-1 genotypes.","volume":"57","author":"Yasui-Furukori","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R11-8-20210129","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00007691-200312000-00003","article-title":"Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone.","volume":"25","author":"Aravagiri","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R12-8-20210129","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00007691-199902000-00017","article-title":"Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors.","volume":"21","author":"Balant-Gorgia","year":"1999","journal-title":"Ther Drug Monit"},{"key":"R13-8-20210129","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia.","volume":"151","author":"Marder","year":"1994","journal-title":"Am J Psychiatry"},{"key":"R14-8-20210129","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0447.2006.00840.x","article-title":"Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.","volume":"114","author":"Nesvag","year":"2006","journal-title":"Acta Psychiatr Scand"},{"key":"R15-8-20210129","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0378-4347(00)00323-6","article-title":"Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection.","volume":"746","author":"Avenoso","year":"2000","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R16-8-20210129","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1570-0232(02)00091-0","article-title":"Simplified high-performance liquid chromatography method for determination of risperidone and 9-hydroxyrisperidone in plasma after overdose.","volume":"772","author":"Titier","year":"2002","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R17-8-20210129","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.chroma.2007.06.023","article-title":"Analytical and semipreparative enantioseparation of 9-hydroxyrisperidone, the main metabolite of risperidone, using high-performance liquid chromatography and capillary electrophoresis validation and determination of enantiomeric purity.","volume":"1163","author":"Danel","year":"2007","journal-title":"J Chromatogr A"},{"key":"R18-8-20210129","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1570-0232(02)01003-6","article-title":"High-performance liquid chromatographic method with diode array detection to identify and quantify atypical antipsychotics and haloperidol in plasma after overdose.","volume":"788","author":"Titier","year":"2003","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R19-8-20210129","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jchromb.2007.02.007","article-title":"Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS\/MS.","volume":"852","author":"Cabovska","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R20-8-20210129","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jchromb.2007.08.007","article-title":"Sensitive liquid chromatography\/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue.","volume":"858","author":"Zhang","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R21-8-20210129","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jchromb.2008.04.041","article-title":"Validated LC-MS\/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine.","volume":"870","author":"De Meulder","year":"2008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R22-8-20210129","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/rcm.2537","article-title":"Liquid chromatography\/tandem mass spectrometry method for the simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma.","volume":"20","author":"Bhatt","year":"2006","journal-title":"Rapid Commun Mass Spectrom"},{"key":"R24-8-20210129","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"R25-8-20210129","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000395069","article-title":"Psychological measurements in psychopharmacology.","volume":"7","author":"Overall","year":"1974","journal-title":"Mod Probl Pharmacopsychiatry"},{"key":"R27-8-20210129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects.","volume":"45","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand"},{"key":"R29-8-20210129","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1023\/A:1007669411738","article-title":"Bioanalytical method validation-a revisit with a decade of progress.","volume":"17","author":"Shah","year":"2000","journal-title":"Pharm Res"},{"key":"R30-8-20210129","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000054932","article-title":"Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms.","volume":"44","author":"Yoshimura","year":"2001","journal-title":"Neuropsychobiology"},{"key":"R31-8-20210129","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1440-1819.2003.01212.x","article-title":"Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone.","volume":"58","author":"Chen","year":"2004","journal-title":"Psychiatry Clin Neurosci"},{"key":"R32-8-20210129","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/ajp.155.4.499","article-title":"Patris M, Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.","volume":"155","author":"Bondolfi","year":"1998","journal-title":"Am J Psychiatry"},{"key":"R33-8-20210129","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00007691-199808000-00004","article-title":"Serum concentrations and side effects in psychiatric patients during risperidone therapy.","volume":"20","author":"Olesen","year":"1998","journal-title":"Ther Drug Monit"},{"key":"R34-8-20210129","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bcp.1999.47.4.460","article-title":"Serum concentrations and clinical effects of risperidone in schizophrenic patients in Singapore-a preliminary report.","volume":"47","author":"Lee","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"R35-8-20210129","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s002130000576","article-title":"Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.","volume":"153","author":"Spina","year":"2001","journal-title":"Psychopharmacology"},{"key":"R36-8-20210129","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00228-007-0430-1","article-title":"Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry.","volume":"64","author":"Hiemke","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"R37-8-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852900003035","article-title":"Dosing atypical antipsychotics.","volume":"13","author":"Cutler","year":"2008","journal-title":"CNS Spectr"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e3181aa4780","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:57:38Z","timestamp":1786039058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-200908000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181aa4780","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}